Leerink Partnrs Increases Earnings Estimates for Alumis

Alumis Inc. (NASDAQ:ALMS - Free Report) - Research analysts at Leerink Partnrs upped their FY2025 EPS estimates for shares of Alumis in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($4.79) for the year, up from their previous estimate of ($5.19). The consensus estimate for Alumis' current full-year earnings is ($8.45) per share. Leerink Partnrs also issued estimates for Alumis' FY2026 earnings at ($4.67) EPS, FY2027 earnings at ($5.70) EPS and FY2028 earnings at ($3.56) EPS.

A number of other equities analysts have also recently weighed in on ALMS. Robert W. Baird assumed coverage on shares of Alumis in a research report on Thursday, October 31st. They set an "outperform" rating and a $25.00 price target on the stock. Baird R W upgraded Alumis to a "strong-buy" rating in a report on Thursday, October 31st. Oppenheimer began coverage on Alumis in a report on Thursday, January 30th. They set an "outperform" rating and a $32.00 price objective on the stock. HC Wainwright lowered their target price on Alumis from $26.00 to $19.00 and set a "buy" rating for the company in a research note on Friday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Alumis in a research note on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $26.57.

Alumis Trading Down 14.8 %

NASDAQ ALMS traded down $0.84 on Friday, reaching $4.83. The company had a trading volume of 323,901 shares, compared to its average volume of 215,892. Alumis has a 52 week low of $4.74 and a 52 week high of $13.53. The stock's 50 day moving average is $7.80 and its 200-day moving average is $10.19.

Institutional Investors Weigh In On Alumis

A number of institutional investors and hedge funds have recently made changes to their positions in ALMS. Millennium Management LLC acquired a new position in shares of Alumis in the second quarter valued at $3,376,000. Towerview LLC grew its stake in Alumis by 22.6% in the 3rd quarter. Towerview LLC now owns 380,000 shares of the company's stock valued at $4,058,000 after buying an additional 70,000 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in Alumis during the third quarter worth approximately $1,160,000. BNP Paribas Financial Markets bought a new stake in shares of Alumis during the third quarter worth approximately $27,000. Finally, MetLife Investment Management LLC bought a new stake in shares of Alumis during the third quarter worth approximately $89,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.